Life sciences firm secures £2 million to boost DNA work

A life sciences firm has secured £2 million support to boost DNA work.

InvenireX has been backed to accelerate commercialisation of technology focused on detecting disease at the earliest biological stage.

The Newcastle-based company’s endeavour – described as “the ultimate needle-in-a-haystack detector” – has been financed by DSW Ventures, XTX Ventures, Cambridge Technology Capital, angel investors and Innovate UK grant funding.

Founded in 2023, InvenireX’s platform uses programmable DNA nanostructures to capture and identify disease markers in real time.

Bosses say the technology has the potential to help detect tumours as small as one millimetre up to a decade earlier, and allow vaccine makers to verify the presence and concentration of active ingredients for the first time at production scale.

Dr Dan Todd, InvenireX founder and chief executive, said: “Our machine could pick up cancer, HIV or sepsis earlier – any disease with a nucleic acid trace.

“We've built the ultimate needle-in-a-haystack detector – a tool that we can put in the hands of scientists to enable the discoveries of tomorrow.”

Doug Quinn, DSW Ventures’ partner, added: “Having invested in InvenireX in early 2024, we've already seen the incredible work its technology can do.

“Now, to help build out the team and validate the commercial opportunity, we're thrilled to be continuing our partnership.

“This access to venture capital is so important to bringing entrepreneurs’ bold and innovative ideas to fruition.”

Looking to promote your product/service to SME businesses in your region? Find out how Bdaily can help →